Research Topics
Subscribe to Research Topics
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Dezima Extends Clinical Development of Dyslipidemia Drug

July 9, 2014 3:02 pm | News | Comments

Dezima Pharma, the biotechnology company developing innovative drugs in the field of dyslipidemia, announced the approval of a Phase 1 pilot study in subjects with isolated, elevated Lipoprotein(a) (Lp(a)), for which additional funding has been secured. Read more...

Domainex Reports Success of COPD Drug

July 9, 2014 2:57 pm | News | Comments

Domainex Ltd, a UK-based drug discovery company developing first-in-class small-molecule inhibitors of two closely-related pro-inflammatory kinases TBK1 and IKK-epsilon announced that its lead compound has demonstrated a more potent effect in a key model of COPD than either roflumulast or a p38 inhibitor. Read more...

Arthritis Drug Misses New Indication Endpoint

July 9, 2014 2:51 pm | News | Comments

Shares of Celgene Corp. slipped in premarket trading Wednesday after the drugmaker said its psoriatic arthritis treatment Otezla missed the main goal of a late-stage study exploring an additional use in a painful spinal joint disorder called ankylosing spondylitis. Read more...


EFPIA Denounces French Law on Off-label Drug Use

July 9, 2014 2:43 pm | News | Comments

EFPIA, the European Federation of Pharmaceutical Industries and Associations, criticized the intent of the French government to broadly enlarge the use of-off label drugs for economic reasons, even if there is an approved drug available. Read more...

Baxter Snags First Drug Candidate from NIH Program

July 9, 2014 1:35 pm | News | Comments

A drug candidate developed by researchers at the NIH’s National Center for Advancing Translational Sciences (NCATS) and its collaborators to treat sickle cell disease has been acquired by Baxter International’s BioScience business. Read more...  

Governor Pushes for Trials of Marijuana Derivative

July 9, 2014 1:12 pm | by Christina A. Cassidy | News | Comments

Georgia's governor is pushing clinical trials for a marijuana-derived drug that proponents say could help treat severe seizure disorders among children. Read more...                         

Forgotten Smallpox Vials Found in Storage Room

July 9, 2014 1:07 pm | by Mike Stobbe, AP Medical Writer | News | Comments

A government scientist cleaning out an old storage room at a research center near Washington made a startling discovery last week- decades-old vials of smallpox packed away and forgotten in a cardboard box. Read more...          

HIV Vaccine Research Team Loses $1.38M Grant

July 9, 2014 12:54 pm | by David Pitt | News | Comments

An AIDS research team at Iowa State University will not get the final $1.38 million payment of a National Institutes of Health five-year grant after a team member admitted last year to faking research results. Read more...        


Cinnamon Could Halt the Progression of Parkinson’s

July 9, 2014 12:49 pm | News | Comments

Neurological scientists have found that using cinnamon, a common food spice and flavoring material, can reverse the biomechanical, cellular and anatomical changes that occur in the brains of mice with Parkinson’s disease (PD). Read more...    

Sandoz Launches Generic Diovan in the U.S.

July 9, 2014 11:24 am | News | Comments

Sandoz announced the U.S. introduction of an authorized generic version of Diovan (valsartan) tablets for the treatment of high blood pressure (HBP) and will market the authorized generic version of Diovan in the same strengths marketed for the branded version of Diovan. Read more...

Insys Updates Timing of NDA for Dronabinol Oral Solution

July 9, 2014 11:18 am | News | Comments

Insys Therapeutics Inc. announced the successful completion of a human abuse study for Dronabinol Oral Solution, its proprietary, orally administered liquid formulation of the synthetic cannabinoid dronabinol in development for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. Read more...

BI Posts Positive Results for Leukemia Drug

July 9, 2014 11:12 am | News | Comments

Results from a Phase 2 study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy, versus LDAC alone in older patients with untreated acute myeloid leukemia (AML) were published in the American Society of Hematology journal Blood. Read more...

Actavis Confirms Generic Ampyra Patent Challenge

July 9, 2014 11:06 am | News | Comments

Actavis plc confirmed that it has filed an Abbreviated NDA with the U.S. FDA seeking approval to market Dalfampridine Extended-release Tablets, 10 mg, a generic version of Acorda Therapeutics' Ampyra, which is indicated as a treatment to improve walking in patients with multiple sclerosis. Read more...


Glioblastoma Cells Disrupt Blood-Brain Barrier

July 9, 2014 10:59 am | News | Comments

Invading glioblastoma cells may hijack cerebral blood vessels during early stages of disease progression and damage the brain’s protective barrier, a study in mice indicates, a finding that may lead to new ways to bring about the death of the tumor, increasing our ability to treat glioblastoma patients. Read more...

CardioCell Launches Phase 2a Chronic Heart Failure Trial

July 8, 2014 3:19 pm | News | Comments

CardioCell LLC announced the start of its Phase 2a clinical trial for chronic heart failure (HF) patients with non-ischemic cardiomyopathy. Read more...                            

Nanoparticles Can Enhance Cisplatin in Chemotherapy

July 8, 2014 2:19 pm | News | Comments

Researchers have developed a new formulation of cisplatin, a common chemotherapy drug, that significantly increases the drug's ability to target and destroy cancerous cells. Read more...                   

Newly Discovered Compounds Could Affect Circadian Rhythm

July 8, 2014 2:08 pm | News | Comments

Scientists have discovered a surprising new role for a pair of compounds that have the potential to alter circadian rhythm. At least one of these compounds could be developed to uncover new therapeutic approaches to a range of disorders. Read more...

AstraZeneca, Max Planck Institute Create Satellite Chemistry Unit

July 8, 2014 10:46 am | News | Comments

AstraZeneca announced an agreement with the Max Planck Institute of Molecular Physiology, Germany, to establish a "satellite unit" in cardiovascular and metabolic disease (CVMD), linked to AstraZeneca’s CVMD Innovative Medicines unit in Mölndal, Sweden, to study new modalities chemistry. Read more...

FDA Accepts NDA for Sanofi's Basal Insulin

July 8, 2014 10:40 am | News | Comments

Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), an investigational basal insulin, formerly abbreviated as "U300." Read more...

Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hep C Treatment

July 8, 2014 10:34 am | News | Comments

Bristol-Myers Squibb announced that the Japanese Ministry of Health, Labor and Welfare has approved Daklinza, a potent, pan-genotypic NS5A replication complex inhibitor, and Sunvepra, a NS3/4A protease inhibitor, providing a new treatment that can lead to cure for many patients in Japan who currently have no treatment options. Read more...

Merck Serono Funds Scientific Innovation

July 8, 2014 10:22 am | News | Comments

Merck Serono, the biopharmaceutical division of Merck, announced the launch of Merck Global Grants – a program that underscores the company’s commitment to funding scientific innovation and independent medical education around the world. Read more...

Researchers Block Memories in Rats, Reduce Drug-Seeking

July 8, 2014 10:15 am | News | Comments

In substance addiction, drug-associated memories are known to powerfully compel craving and drug seeking behavior. Research by Prof. Barry Everitt at the University of Cambridge, UK, indicates that disrupting the brain's memory pathways might point towards future addiction therapy approaches. Read more...

Personalized Immunotherapy for Leukemia Named Breakthrough Therapy

July 7, 2014 2:36 pm | News | Comments

A University-developed personalized immunotherapy was awarded the FDA's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia. The therapy, known as CTL019, is the first personalized cellular therapy for the treatment of cancer to receive this classification. Read more...

NIH Awards SBIR Grant for Epigenetic Database

July 7, 2014 2:25 pm | News | Comments

Reaction Biology Corp. (RBC) announced that it has been awarded a Phase 1 SBIR grant from the National Center for Advancing Translational Sciences to create a database of epigenetic drug interactions. Read more...           

Animal Vaccines Should Guide Malaria Research

July 7, 2014 2:07 pm | News | Comments

Research into vaccines for malaria in humans should be guided by the success shown in producing effective vaccines for malaria-like diseases in animals, according to a new study. Read more...                  

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.